Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data Exousia Bio, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2023
FY2024
FY2025
Revenue
0
0.01
0
Cost of revenue
0
0.01
0.01
Gross profit
0
0
-0
General and administrative
0.06
0.03
0.03
Operating expenses
0.06
0.03
0.03
Operating income
-0.06
Other non-operating income
0
0
0.09
Pre-tax income
-0.06
-0.03
0.05
Income tax
0
0
0
Net income
-0.06
-0.03
0.05
EBITDA
-0.05
EPS, basic
0.00
0.00
0.00
EPS, diluted
0.00
0.00
0.00
Shares, basic (weighted)
5.69
7.78
7.78
Shares, diluted (weighted)
5.69
7.78
7.78
Balance sheet
FY2023
FY2024
FY2025
Cash and equivalents
0.01
0
0
Receivables
0
0.01
0
Total current assets
0.01
0.01
0
Property, plant and equipment
0.01
0
0
Intangible assets
0.02
0.01
0
Other non-current assets
0
Total assets
0.04
0.03
0
Accounts payable
0
Accrued liabilities
0
0
0
Total current liabilities
0
0.01
0
Total liabilities
0.07
0.08
0
Paid-in capital
0.03
0.03
0.03
Retained earnings
-0.06
-0.08
-0.03
Shareholders' equity
-0.03
-0.05
0
Total equity
-0.03
-0.05
0
Total liabilities and equity
0.04
0.03
0
Shares outstanding
7.78
7.78
7.78
Cash flow statement
FY2023
FY2024
FY2025
Net income
-0.06
-0.03
0.05
Depreciation and amortization
0.01
0.01
0
Change in receivables
0
-0.01
0.01
Cash from operations
-0.04
-0.01
-0
Cash from investing
0
0
0
Stock issued
0.03
0
0
Cash from financing
0.04
0.01
0
Net change in cash
-0
-0.01
-0
Interest paid
0
0
0
Income taxes paid
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to November 30, 2025; growth uses fiscal years. Valuation uses the share price of $0.01 on October 22, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-0.3%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-0.3%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-67.4%
Revenue vs the same period a year earlier. Only from a positive base.
Gross profit growth, 1y
-291.0%
Gross profit vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-100.0%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
0.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.00x
Current assets / current liabilities.
Quick ratio
0.00x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.00x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.00
Revenue / diluted weighted shares.
Operating cash flow per share
$0.01
Cash from operations / diluted weighted shares.
Book value per share
$0.31
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
0.03x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.03x
Market cap / tangible book value, when positive.
P/OCF
8.77x
Market cap / cash from operations, when positive.
Earnings yield
-10.1%
Net income / market cap (the inverse of P/E).
What was Exousia Bio, Inc.'s revenue in fiscal 2025?
Exousia Bio, Inc. reported revenue of $3.8K for fiscal 2025, 67.4% lower than the year before.
Was Exousia Bio, Inc. profitable in fiscal 2025?
Yes. Net income was $51.4K, a net margin of 1,370.5%.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.